Bio­gen vet Alp­na Seth jumps to George Scan­gos' biotech start­up; Top FDA sci­en­tist makes a leap to PhRMA

Alp­na Seth

⇨ Long­time Bio­gen ex­ec Alp­na Seth has de­cid­ed to head west, way west, to re­join ex-Bio­gen CEO George Scan­gos as COO of his up­start biotech. He left the big com­pa­ny in Ju­ly, ac­cord­ing to the Boston Busi­ness Jour­nal.

⇨ With Ed­uar­do Sanchiz fol­low­ing through on step­ping down from the helm at Almi­rall, the com­pa­ny has re­cruit­ed a se­nior Sanofi ex­ec­u­tive for its new CEO. Pe­ter Guenter has spent the past 22 years at Sanofi, most re­cent­ly as ex­ec­u­tive vice pres­i­dent di­a­betes and car­dio­vas­cu­lar glob­al busi­ness unit.

PhRMA has brought in a top clin­i­cal re­search ex­pert — and se­nior FDA vet — to help guide its lob­by­ing work in Wash­ing­ton, DC. Richard Mosci­c­ki is jump­ing from his post as deputy di­rec­tor for sci­ence op­er­a­tions at CDER right over to a new role as chief med­ical of­fi­cer at PhRMA, which has been do­ing its best to spot­light the in­dus­try’s multi­bil­lion-dol­lar in­vest­ment in drug R&D as it seeks a help­ful stance from the fed­er­al gov­ern­ment on a score of key is­sues. Af­ter an in­ter­nal re­view that led the group to cut ties with com­pa­nies that had a less-than-stel­lar track record in in­vest­ing in R&D, Mosci­c­ki will bring an in­sid­er’s knowl­edge of the agency to his new role lead­ing sci­ence and reg­u­la­to­ry ad­vo­ca­cy ef­forts

Fred Cal­lori

⇨ Chris­t­ian Mey­er is the new chief med­ical of­fi­cer at Ther­a­chon. Mey­er’s re­sume in­cludes a stint as the CMO at uniQure where he had a help­ing hand in bring­ing the world’s most ex­pen­sive but no longer in pro­duc­tion drug Gly­bera to the mar­ket.

Cona­tus Phar­ma­ceu­ti­cals has bagged Kei­th Mar­shall for their EVP-COO-CFO com­bo gig.

⇨ Karolin­s­ka De­vel­op­ment’s lat­est CEO is Vik­tor Dr­vota, who re­placed Jim Van heus­den. Chair­man Bo Jes­per Hansen al­so de­cid­ed to step down and was re­placed by board mem­ber Niclas Adler.

Hu­mani­gen shares $HGEN were blitzed this week, right af­ter the com­pa­ny named Greg Jester as its new CFO.

Chris Garabe­di­an’s new com­pa­ny Xon­toge­ny has named Fred Cal­lori as SVP of cor­po­rate de­vel­op­ment. Cal­lori is a for­mer part­ner at Choate Hall & Stew­art with ex­pe­ri­ence cre­at­ing and fund­ing life sci­ences com­pa­nies.

George Scangos (L) and Marianne De Backer

Pi­o­neer­ing biotech icon George Scan­gos hands in his re­tire­ment pa­pers — and this time it’s for re­al

George Scangos, one of the all-time great biotech CEOs, says the time has come to turn over the reins one last time.

The 74-year-old biotech legend spent close to three decades in a CEO post. The first was at Exelixis — which is still heavily focused on a drug Scangos advanced in the clinic. The second “retirement” was at Biogen, where he and his team were credited with a big turnaround with the now fading MS blockbuster Tecfidera. And the third comes at Vir, where he traded in his Big Biotech credentials for a marquee founder’s role back on the West Coast, hammering out a Covid-19 alliance with Hal Barron — then R&D chief at GSK — and breaking new ground on infectious diseases with some high-powered venture players.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jeanne Loring, director of the Center for Regenerative Medicine (Credit: Jamie Scott Lytle)

A stem cell pi­o­neer sent an ex­per­i­ment in­to space. Pa­tients are the next fron­tier

Last July, Jeanne Loring stood on a dirt road surrounded by Florida swampland and watched as a nearby SpaceX rocket blasted into the sky. The payload included a very personal belonging: cell clusters mimicking parts of her brain.

For more than two decades, Loring has been at the forefront of a stem cell field that always seems on the brink of becoming the next thing in medicine, but has been slow to lift off.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA re­ports ini­tial 'no sig­nal' for stroke risk with Pfiz­er boost­ers, launch­es con­comi­tant flu shot study

The FDA hasn’t detected any potential safety signals, including for stroke, in people aged 65 years and older who have received Pfizer’s bivalent Covid booster, one senior official told members of the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Thursday.

The update comes as the FDA and CDC investigate a “preliminary signal” that may indicate an increased risk of ischemic stroke in older Americans who received Pfizer’s updated shot.

FDA cuts off use for As­traZeneca’s Covid-19 ther­a­py Evusheld

The FDA has stopped use of another drug as a result of the new coronavirus variants. On Thursday, the agency announced that AstraZeneca’s antibody combo Evusheld, which was an important prevention option for many immunocompromised people and others, is no longer authorized.

The FDA said it made its decision based on the fact that Evusheld works on fewer than 10% of circulating variants.

Evusheld was initially given emergency authorization at the end of 2021. However, as Omicron emerged, so did studies that showed Evusheld might not work against the dominant Omicron strain. In October, the FDA warned healthcare providers that Evusheld was useless against the Omicron subvariant BA.4.6. It followed that up with another announcement earlier this month that it did not think Evusheld would work against the latest Omicron subvariant XBB.1.5.

In­vestor 'misalign­men­t' leads to tR­NA biotech's shut­ter­ing

A small biotech looking to carve a lane in the tRNA field has folded, an investor and a co-founder confirmed to Endpoints News.

Similar to Flagship’s Alltrna and other upstarts like Takeda-backed hC Bioscience, the now-shuttered Theonys was attempting to go after transfer RNA, seen as a potential Swiss Army knife in the broader RNA therapeutics space. The idea is that one tRNA drug could be used across a galaxy of disorders and diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.

#JPM23: What's re­al­ly dri­ving the cost of health­care and drugs in 2023?

Executive Editor Drew Armstrong spoke with PhRMA CEO Steve Ubl, EmsanaRx CEO Greg Baker and ICER President Steve Pearson about how the debate over drug costs has changed (or not) in the last decade, the shifting payer landscape and why there seems to be so little movement on drug rebates. This transcript has been edited for brevity and clarity.

Drew Armstrong:

So first of all, thank you to everybody for being here and for our panel for being here. Incredibly excited to have this discussion on the cost of healthcare and drugs and what’s driving that. We’re here with Steve Ubl, the head of PhRMA. Thank you so much. Steve Pearson from ICER, and Greg Baker from EmsanaRx. I want to start this conversation with a little bit of a personal reminiscence. So about almost 10 years exactly. I was a reporter back in my previous job and I was covering drug pricing and Gilead had just launched their hepatitis C drug and I was having a conversation with another Steve over at Express Scripts and he made some comments essentially about how they intended to launch a price war over hepatitis C therapies.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pa­tient death spurs tri­al halt for Ma­gen­ta Ther­a­peu­tics

Magenta Therapeutics is pausing an early-stage clinical trial after a patient died. The death was deemed to be possibly related to its drug, MGTA-117.

The biotech said the pause of the Phase I/II trial is voluntary and gives it time to review all available data before deciding what to do next. It’s also reported the known information to the FDA.

The dose-escalation trial was designed to test whether MGTA-117, an antibody-drug conjugate, could serve as a more targeted alternative to high-intensity chemotherapy as a conditioning agent for cancer patients who are set to receive a stem cell transplant. It recruited patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

In a win for Re­gen­eron, No­var­tis' sy­ringe for AMD drug de­clared 'un­patentable'

Regeneron has won a patent case against Swiss pharma giant Novartis over the delivery system for its eye drug Eylea.

The US Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable” and handed the victory to Regeneron and its AMD drug Eylea.

In the initial complaint in 2020, Novartis alleged to the US International Trade Commission that certain pre-filled syringes for the intravitreal injection, and ultimately Regeneron’s delivery system for Eylea, were infringing on Novartis’ patent. Regeneron filed a petition to review Novartis’ claims in 2021.

'Tis the sea­son: GSK ad­dress­es win­ter virus surges with celebri­ty and in­flu­encer vac­cine aware­ness cam­paigns

GSK is rounding up the usual suspects this winter — flu, respiratory syncytial and even shingles viruses — for multiple marketing efforts all aimed at encouraging vaccinations.

Mom influencers take center stage in its “Flu is a Family Affair” campaign to reach family decision-makers or “chief health officers.” GSK is asking them in the digital campaign to take care of themselves, and take the family along, when they go to the pharmacy or doctor’s office for a flu vaccine.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.